Ligand Pharmaceuticals Incorporated (LGND)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 77.53% | 76.13% | 79.49% | 84.88% | 91.98% | 80.15% | 77.97% | 76.20% | 75.94% | 82.13% | 83.16% | 78.06% | 77.56% | 77.45% | 77.42% | 83.74% | 83.68% | 85.63% | 86.22% | 88.93% |
| Operating profit margin | 2.32% | 6.67% | 5.17% | -2.09% | 6.66% | -5.21% | -3.38% | -1.33% | -10.80% | 2.39% | 8.29% | 23.99% | 27.26% | 28.17% | 25.99% | 12.85% | 13.86% | 3.11% | -3.52% | -14.26% |
| Pretax margin | 1.51% | 38.59% | 37.32% | 100.05% | 46.04% | 43.95% | 44.81% | 36.67% | 1.92% | -11.15% | -5.22% | 7.99% | 17.07% | 21.01% | 12.25% | 12.30% | -5.65% | -15.40% | -24.01% | -69.56% |
| Net profit margin | -2.41% | 29.68% | 29.69% | 79.30% | 37.80% | 11.01% | 16.12% | 12.36% | -13.85% | -8.62% | -3.13% | 9.00% | 20.78% | 24.87% | 19.03% | 18.83% | -1.60% | -11.23% | -19.51% | -55.63% |
The profitability ratios of Ligand Pharmaceuticals Incorporated have shown fluctuations over the periods analyzed.
- Gross profit margin has generally been high, fluctuating between 75.94% and 91.98% during the observed periods. There was a gradual decrease in the margin from 91.98% on December 31, 2023, to 76.13% on September 30, 2024, before a slight increase to 77.53% on December 31, 2024.
- Operating profit margin has displayed significant variations, ranging from -14.26% on March 31, 2020, to 28.17% on September 30, 2021. The margin experienced both positive and negative trends, with a notable peak on September 30, 2021, followed by a decrease to 2.32% on December 31, 2024.
- Pre-tax margin showed a mix of negative and positive margins, with the lowest at -69.56% on March 31, 2020, and the highest at 100.05% on March 31, 2024. There was a significant improvement in margins from December 31, 2022, to March 31, 2024.
- Net profit margin varied between -55.63% on March 31, 2020, and 79.30% on March 31, 2024. The company went through fluctuations, marked by negative margins in some periods and significant improvements in profitability in others, with negative margins recorded on December 31, 2024.
Overall, there have been fluctuations in the profitability ratios of Ligand Pharmaceuticals Incorporated, indicating varying levels of success in generating profits over the analyzed periods.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 0.41% | 1.06% | 0.80% | -0.27% | 1.05% | -1.04% | -0.83% | -0.36% | -3.11% | 550.05% | 1.85% | 5.81% | 5.81% | 6.07% | 5.21% | 2.07% | 1.90% | 0.36% | -0.36% | -1.32% |
| Return on assets (ROA) | -0.43% | 4.74% | 4.57% | 10.27% | 5.96% | 2.20% | 3.97% | 3.32% | -3.99% | -1,983.25% | -0.70% | 2.18% | 4.42% | 5.36% | 3.81% | 3.03% | -0.22% | -1.29% | -1.98% | -5.16% |
| Return on total capital | -12.68% | -5.92% | -7.23% | 1.43% | 1.88% | 3.06% | 6.74% | 6.37% | 6.47% | 1,436.52% | 1.41% | 2.92% | 3.13% | 5.30% | 3.28% | 2.85% | -0.73% | -2.77% | -3.99% | -6.92% |
| Return on equity (ROE) | -0.49% | 5.38% | 5.11% | 11.63% | 7.08% | 2.54% | 4.53% | 4.17% | -5.09% | -2,554.41% | -0.94% | 3.04% | 7.01% | 8.41% | 6.09% | 5.26% | -0.42% | -2.31% | -3.55% | -9.24% |
Ligand Pharmaceuticals Incorporated's profitability ratios have shown fluctuating trends over the reported periods. The Operating Return on Assets (Operating ROA) improved significantly from -1.32% in March 2020 to a peak of 550.05% in September 2022, before declining to -0.27% in March 2024. This indicates both operational efficiency and asset utilization.
Similarly, the Return on Assets (ROA) also depicted volatility, with a notable upturn from negative values to a peak of 10.27% in March 2024, suggesting enhanced profitability relative to the total assets owned by the company.
The Return on Total Capital exhibited substantial variability, with a remarkable increase to 1,436.52% in September 2022, followed by a downward trend to -12.68% in December 2024, indicating the challenges faced in generating returns relative to the total capital employed.
Furthermore, the Return on Equity (ROE) displayed significant fluctuations, reaching a high of 11.63% in March 2024 after experiencing negative values in the past, illustrating the company's ability to generate profits from shareholders' equity.
Overall, while Ligand Pharmaceuticals Incorporated experienced fluctuations in its profitability ratios, it is essential for stakeholders to closely monitor these metrics to assess the company's financial performance and stability over time.